Fleroxacin Injection

This product is a fluoroquinolone antibacterial drug. It has strong antibacterial effects on Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus, Salmonella typhi, Salmonella paratyphi, Shigella, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter, Serratia marcescens, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Moracata, Legionella pneumophila, Neisseria gonorrhoeae, etc. It also has moderate antibacterial effects on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. In recent years, bacterial resistance to fluoroquinolones has increased significantly, especially in Escherichia coli, with a resistance rate of more than 50%. The mechanism of action of this product is to inhibit the bacterial DNA gyrase and thus kill bacteria.

Fleroxacin: 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid. [Molecular formula] C17H18F3N3O3 [Molecular weight] 369.34

This product belongs to the fluoroquinolone antibacterial drug, suitable for moderate to severe respiratory system, urinary system, digestive system and skin and soft tissue infections, sepsis, gynecological infections, etc. caused by sensitive bacteria such as Enterobacteriaceae such as Klebsiella pneumoniae, Proteus, Salmonella, Escherichia coli, methicillin-sensitive Staphylococcus and other sensitive bacteria.

Inject slowly by intravenous drip in a dark place, 0.2-0.4 g at a time, once a day, diluted in 250-500 ml of 5% glucose injection.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea, vomiting, and loss of appetite. 2. Central nervous system reactions may include dizziness, headache, excitement, drowsiness, or insomnia. 3. Allergic reactions include rash, skin itching, and occasionally exudative erythema multiforme and angioneurotic edema. A small number of patients have photosensitivity reactions. 4. A small number of patients may experience increased blood aminotransferase and blood urea nitrogen and decreased peripheral white blood cells, which are mostly mild and transient. 5. Occasionally, the following may occur: 1. Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors. 2. Manifestations of interstitial nephritis such as hematuria, fever, and rash. 3. Crystalluria, more common when used in high doses. 4. Joint pain. 5. Phlebitis.

It is contraindicated for patients who are allergic to this product or quinolones, pregnant women, lactating women, patients under 18 years of age and patients with epilepsy.

Precautions during pregnancy and lactation: Pregnant and lactating women are prohibited from using.

1. The aluminum and magnesium contained in didanosine (DDI) preparations can chelate with fluoroquinolones and should not be used together. 2. Urine alkalinizers can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 3. Probenecid can delay the excretion of this product, increase the blood concentration of this product and produce toxicity.

Keep away from light and store in a sealed container.

5 ml: 0.4 g

Yabao Pharmaceutical Group Co., Ltd.

• Founded in:

  1999-01-26

• Address:

  No. 43, Fumin Road, Ruicheng County, Yuncheng City, Shanxi Province

• Tax NO.:

  91140000701108049W

• Registered Funds:

  720,000,940 yuan

• Website:

  Log in to view

• Email:

  Log in to view